| 8.09 -0.35 (-4.15%) | 04-16 10:49 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.51 | 1-year : | 13.45 |
| Resists | First : | 9.85 | Second : | 11.51 |
| Pivot price | 8.7  |
|||
| Supports | First : | 7.57 | Second : | 6.15 |
| MAs | MA(5) : | 8.77 |
MA(20) : | 8.71 |
| MA(100) : | 6.3 |
MA(250) : | 6.68 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 43.2 |
D(3) : | 52.8 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 9.85 | Low : | 4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ATNM ] has closed above bottom band by 31.0%. Bollinger Bands are 0.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.1 - 9.17 | 9.17 - 9.22 |
| Low: | 8.17 - 8.23 | 8.23 - 8.27 |
| Close: | 8.36 - 8.45 | 8.45 - 8.52 |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Fri, 12 Apr 2024
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? - Yahoo Movies Canada
Fri, 05 Apr 2024
Analysts Issue Forecasts for Actinium Pharmaceuticals, Inc.'s FY2024 Earnings (NYSEAMERICAN:ATNM) - Defense World
Thu, 04 Apr 2024
FY2024 EPS Estimates for Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Reduced by HC Wainwright - Defense World
Thu, 28 Mar 2024
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE ... - Barchart
Fri, 22 Mar 2024
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum - Barchart
Tue, 19 Mar 2024
Should You Buy Actinium Pharmaceuticals Inc (ATNM) Stock Tuesday Morning? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 25.8 (%) |
| Shares Short | 2,040 (K) |
| Shares Short P.Month | 2,000 (K) |
| EPS | -1.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.2 % |
| Return on Equity (ttm) | -87.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -4.33 |
| PEG Ratio | 0 |
| Price to Book value | 5.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|